ORIC Pharmaceuticals (ORIC.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

Oric Pharmaceuticals Presents Enozerinib Trial Data at ESMO Asia Conference

21:01

Dec1

Oric Pharmaceuticals to Release New Clinical Trial Data on Enozertinib at ESMO Asia

13:00

Nov20

Evercore ISI Group Initiates Coverage of Oric Pharmaceuticals Stock with an 'Outperform' Rating

14:20

Evercore ISI Issues Buy Rating on ORIC Pharmaceuticals: ORIC-944 Poised to Become Blockbuster Drug

10:12

Nov17

Wedbush Reiterates ORIC Pharmaceuticals' 'Outperform' Rating

04:21

Nov14

ORIC Pharmaceuticals released FY2025 Q3 earnings on November 13 (EST), actual EPS USD -0.3293 (forecast USD -0.4055)

04:00

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -32.59 M, EPS -0.3293

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -36.36 M, EPS -0.4653

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -30.02 M, EPS -0.4225

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change